Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 8/20 | 0.32 |
| ▸ | FGFR2 | P21802 | 8/20 | 0.32 |
| ▸ | FGFR4 | P22455 | 8/20 | 0.32 |
| ▸ | FGFR3 | P22607 | 8/20 | 0.32 |
| ▸ | KDR | P35968 | 7/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4068528 | 0.86 | FGFR1 (0.34) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL4068215 | 0.83 | FGFR1 (0.35) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL2693461 | 0.81 | TSHR (0.41) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL4067316 | 0.72 | DUT (0.37) | DUT | |
| SCHEMBL2127136 | 0.71 | FGFR1 (0.37) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL2125333 | 0.71 | FGFR1 (0.37) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL2124334 | 0.69 | MEN1 (0.40) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL2129624 | 0.69 | CXCR4 (0.42) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL2124123 | 0.67 | MEN1 (0.46) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL2123754 | 0.67 | FGFR1 (0.35) | FGFR1FGFR2FGFR4FGFR3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325992-A1 | COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-2055705-A1 | COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF | Ono Pharmaceutical CO., LTD. (JP) | 2009-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325992-A1 | COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF | CXCR4, CXCL12, CXCR1 | DUT 4295/4885FGFR1 412/4885FGFR2 1420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.